Exit Lincoln Pharma, prefer Syngene: Gaurang Shah

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Gaurang Shah of Geojit BNP Paribas Financial Services told CNBC-TV18, "We did see a huge rally in the lesser known midcap pharma and small cap pharma for considerable amount of upside and I would request whenever you hear this kind of newsflow immediately alarm bells should ring as to how much of hit the company is going to take in terms of its revenue and what is going to be the impact of a particular injectible or a drug which is in question. How much of sales and profitability etc is the part on the entire balance sheet.""My sense is that if one can move out from Lincoln Pharma either at current levels or at pull back then there is one particular company which got listed recently that is Syngene International Limited. As a disclosure we have recommended a subscribe in the Initial Public Offering (IPO) and growth of the company looks quite comforting to us.""If not Syngene and if one wants to look at largecap frontline pharma names then again as a disclosure we have a coverage on Sun Pharma, Lupin and Dr Reddy's. All these three names in the recent times have corrected and they are at a level wherein it is favourable in terms of risk reward and whatever issues which are there in terms of manufacturing facility or warning letters by US Food and Drugs Administration (FDA) the managements are quite capable of resolving this negativity newsflow in a matter of time. So, from a long term point of view these are preferred investment ideas from our side," he added.